Menlo Therapeutics attracts $50 mln Series C

Menlo Park, California-based Menlo Therapeutics Inc, a pharmaceutical company focused on treating chronic pruritus and chronic cough, has raised $50 million in Series C funding. VenBio led the round with participation from other investors that included Novo Holdings A/S, Rock Springs Capital, Aisling Capital, Bay City Capital, Vivo Capital, Presidio Partners, Remeditex and F-Prime Capital. In addition to the funding, Dr. Aaron Royston of VenBio will join Menlo Therapeutics’ board of directors.

Source: Press Release